ERBB2 and neoplasm: Nonetheless, despite the careful application of criteria to define HER2-positivity, heterogeneous intratumoral HER2 staining and/or HER2 gene amplification with HER2-positive and HER2-negative regions within the same tumor have been reported in 6–36% of tumors scored as HER2-positive.5